adobe.stock.com - CathyA month after China publicly revealed its bioeconomy priorities under its 15th Five Year Plan, the European Commission released an updated EU Bioeconomy Strategy — and the contrast could hardly be sharper. While China bets on a bold mix of AI, bioengineering and synthetic biology to replace fossil based industrial products with recombinant and cell free systems, the EU remains anchored in a more traditional vision focused on the valorisation of agricultural output and industrial waste. By contrast, the UK has taken a more modern approach, heavily investing in engineering biology — the use of reprogrammed microorganisms to produce industrial goods — as a key pillar of its biotech and bioeconomy strategy.
Tag Archive for: manufacturing
Celonic GroupThe Celonic Group and CARBOGEN AMCIS AG have formed a strategic alliance to offer a fully integrated Antibody Drug Conjugate (ADC) development and manufacturing platform. This partnership combines Celonic’s biologics expertise with CARBOGEN AMCIS’s payload synthesis and conjugation capabilities, creating a seamless, end-to-end solution for ADC developers.
Rezon BioThe global biologics industry is entering a new phase of maturity. As costs tighten and timelines accelerate, CDMOs must deliver uncompromised quality while driving efficiency. Rezon Bio, an EU-based biologics CDMO with state-of-the-art facilities and a client-centric approach, was established to meet biotech and pharmaceutical client needs with agility, pragmatism, and trust.
AstraZenecaAstraZeneca announces a US$50 billion investment in the USA amid pharma’s transatlantic drift. Virgina is set to become the multi-billion-dollar drug manufacturing hub.
Microsynth AGTherapeutic oligonucleotides are rapidly transforming drug development by enabling precise gene modulation strategies. Microsynth empowers biotech, pharmaceutical, and academic researchers with high-quality therapeutic oligonucleotides, supporting every stage from sequence design to preclinical development. With tailored solutions, advanced automation, and expert design support, we accelerate your therapeutic programmes with precision and speed.
Fuse VectorsFuse Vectors has secured US$5.2m in pre-seed financing to revolutionise gene therapy manufacturing with its cell-free viral vector technology. The Danish company is aiming to make treatments more accessible and cost-effective by streamlining production.
When businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.